Fig. 5

SIRT7 up-regulation eradicates anti-tumor immunity. a, b Tumor volumes and weights of B16F10 xenografts with or without the knockdown of SIRT7. c Immunofluorescence staining of CD8α in B16F10 xenografts with or without the knockdown of SIRT7. Scale bar, 50 μm. d FACS of CD3⁺in CD45⁺cells and CD8⁺ in CD3⁺ TILs from B16F10 xenografts with indicated treatment and corresponding quantification. e GZMB⁺CD8⁺ TILs from B16F10 xenografts with indicated treatment and corresponding quantification. f A schematic view of the treatment plan that C57BL/6 mice burdened with negative control (sh-NC) and SIRT7 shRNA Lentivirus (sh-SIRT7-1)-transfected B16F10 tumors with or without CD8α mAb treatment and images of isolated tumors from mice that with indicated treatment. Tumor volumes and weights in each group were calculated and displayed in (g) and (h). Symbols of one dot indicates one mouse, and the error bars are mean with ±S.D. P value was calculated by two-tailed Student’s t-test. *P < 0.05, **P < 0.01, ***P < 0.001